港股异动 | 映恩生物-B(09606)早盘涨近3% DB-1418获FDA授予快速通道资格

智通财经11-12

智通财经APP获悉，映恩生物-B(09606)早盘涨近3%，截至发稿，涨2.23%，报301港元，成交额1809.69万港元。消息面上，据映恩生物官微消息，公司合作伙伴Avenzo Therapeutics, Inc.(以下简称"Avenzo")宣布，美国食品药品监督管理局(FDA)已授予其潜在同类最佳EGFR/HER3双特异性抗体药物偶联物(ADC)AVZO-1418/DB-1418快速通道资格...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2582895312?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-12 09:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582895312","market":"hk","top_or_hot":-1,"title":"港股异动 | 映恩生物-B(09606)早盘涨近3% DB-1418获FDA授予快速通道资格","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，映恩生物-B(09606)早盘涨近3%，截至发稿，涨2.23%，报301港元，成交额1809.69万港元。消息面上，据映恩生物官微消息，公司合作伙伴Avenzo Therapeutics, Inc.(以下简称\"Avenzo\")宣布，美国食品药品监督管理局(FDA)已授予其潜在同类最佳EGFR/HER3双特异性抗体药物偶联物(ADC)AVZO-1418/DB-1418快速通道资格...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1368089.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 映恩生物-B(09606)早盘涨近3% DB-1418获FDA授予快速通道资格</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 映恩生物-B(09606)早盘涨近3% DB-1418获FDA授予快速通道资格\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-12 09:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1368089.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，映恩生物-B(09606)早盘涨近3%，截至发稿，涨2.23%，报301港元，成交额1809.69万港元。消息面上，据映恩生物官微消息，公司合作伙伴Avenzo Therapeutics, Inc.(以下简称\"Avenzo\")宣布，美国食品药品监督管理局(FDA)已授予其潜在同类最佳EGFR/HER3双特异性抗体药物偶联物(ADC)AVZO-1418/DB-1418快速通道资格...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1368089.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1368089.html","article_id":"2582895312","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582895312","pubTimestamp":1762911334,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，映恩生物-B早盘涨近3%，截至发稿，涨2.23%，报301港元，成交额1809.69万港元。消息面上，据映恩生物官微消息，公司合作伙伴Avenzo Therapeutics, Inc.宣布，美国食品药品监督管理局已授予其潜在同类最佳EGFR/HER3双特异性抗体药物偶联物AVZO-1418/DB-1418快速通道资格。今年初，映恩生物与Avenzo达成独家许可协议，根据协议约定，Avenzo在全球范围内负责AVZO-1418/DB-1418的开发、生产和商业化。旨在评估AVZO-1418/DB-1418作为单药及联合疗法在晚期实体瘤患者中的安全性、耐受性和初步临床活性。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","09606":"映恩生物-B","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","BK4552":"Archegos爆仓风波概念","DB":"德意志银行","BK4118":"综合性资本市场","BK4585":"ETF&股票定投概念","BK4588":"碎股","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","BK4566":"资本集团","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元"},"translate_title":"Changes in Hong Kong stocks | Yingen Bio-B (09606) rose nearly 3% in early trading DB-1418 was granted fast track qualification by the FDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DB":1.5,"09606":1.5},"content_text":"智通财经APP获悉，映恩生物-B(09606)早盘涨近3%，截至发稿，涨2.23%，报301港元，成交额1809.69万港元。消息面上，据映恩生物官微消息，公司合作伙伴Avenzo Therapeutics, Inc.(以下简称\"Avenzo\")宣布，美国食品药品监督管理局(FDA)已授予其潜在同类最佳EGFR/HER3双特异性抗体药物偶联物(ADC)AVZO-1418/DB-1418快速通道资格。据介绍，Avenzo是美国的一家致力于开发下一代肿瘤疗法的临床阶段生物技术公司。今年初，映恩生物与Avenzo达成独家许可协议，根据协议约定，Avenzo在全球范围内(不包括大中华区)负责AVZO-1418/DB-1418的开发、生产和商业化。此次快速通道资格的授予是针对不可切除的局部晚期或转移性非小细胞肺癌(NSCLC)患者的治疗适应症，这些患者携带表皮生长因子受体EGFR 19号外显子缺失或21号外显子L858R突变，且在EGFR酪氨酸激酶抑制剂(TKI)治疗后出现疾病进展。目前，AVZO-1418/DB-1418正在开展一项开放标签， 1/2期首次人体临床试验。旨在评估AVZO-1418/DB-1418作为单药及联合疗法在晚期实体瘤患者中的安全性、耐受性和初步临床活性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582895312","isCrawlerRequest":true}